NCT01929642View on ClinicalTrials.gov

Rapalogues for Autism Phenotype in TSC: A Feasibility Study

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

July 31, 2016

Study Completion Date

August 31, 2016

Conditions
Tuberous Sclerosis ComplexSelf-injuryAutism
Interventions
DRUG

Sirolimus

DRUG

Everolimus

Trial Locations (1)

21205

Kennedy Krieger Institute, Baltimore

All Listed Sponsors
lead

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

OTHER

NCT01929642 - Rapalogues for Autism Phenotype in TSC: A Feasibility Study | Biotech Hunter | Biotech Hunter